|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2004-10-6
|
|
pubmed:abstractText |
Although randomized trials have clearly demonstrated the clinical efficacy with regimens of platelet glycoprotein IIb/IIIa antagonists that result in >80% inhibition of baseline platelet aggregation in percutaneous coronary intervention (PCI), there are no data available concerning the optimal duration of infusion of these agents. In an era when the length of hospitalization has a major impact on health care costs, the determination of the optimal duration of the infusion of these drugs after PCI is of great relevance. The investigators therefore sought to determine the optimal length of the infusion of eptifibatide after PCI by analyzing the outcomes of patients enrolled in the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy trial who were randomized to treatment with eptifibatide.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0002-9149
|
|
pubmed:author |
pubmed-author:DeryJean-PierreJP,
pubmed-author:ESPRIT substudy,
pubmed-author:GilchristIan CIC,
pubmed-author:HellkampAnne SAS,
pubmed-author:JohnsonBrent ABA,
pubmed-author:JosephDianeD,
pubmed-author:KittMichael MMM,
pubmed-author:MuhlesteinJ BrentJB,
pubmed-author:O'sheaJ ConorJC,
pubmed-author:PieperKaren SKS,
pubmed-author:RebeizAbdallah GAG,
pubmed-author:SlaterJamesJ,
pubmed-author:TchengJames EJE,
pubmed-author:TsiatisAnastasios AAA
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
94
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
926-9
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:15464679-Angioplasty, Balloon, Coronary,
pubmed-meshheading:15464679-Biological Markers,
pubmed-meshheading:15464679-Coronary Disease,
pubmed-meshheading:15464679-Creatine Kinase,
pubmed-meshheading:15464679-Creatine Kinase, MB Form,
pubmed-meshheading:15464679-Double-Blind Method,
pubmed-meshheading:15464679-Humans,
pubmed-meshheading:15464679-Infusions, Intra-Arterial,
pubmed-meshheading:15464679-Isoenzymes,
pubmed-meshheading:15464679-Myocardial Infarction,
pubmed-meshheading:15464679-North America,
pubmed-meshheading:15464679-Peptides,
pubmed-meshheading:15464679-Platelet Aggregation Inhibitors,
pubmed-meshheading:15464679-Platelet Glycoprotein GPIIb-IIIa Complex,
pubmed-meshheading:15464679-Postoperative Complications,
pubmed-meshheading:15464679-Survival Analysis,
pubmed-meshheading:15464679-Time Factors,
pubmed-meshheading:15464679-Treatment Outcome
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Optimal duration of eptifibatide infusion in percutaneous coronary intervention (an ESPRIT substudy).
|
|
pubmed:affiliation |
Duke Clinical Research Institute, Durham, North Carolina, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
